



Figure S4. IRE1α inhibition attenuates CT26 tumor growth. (A, B) Animals were inoculated s.c. with parental or IRE1α KO CT26 cells and tumor growth was measured over 27 days. **(B)** IB analysis of IRE1α expression and activation.





Figure S4. IRE1α inhibition attenuates CT26 tumor growth. (A, B) Animals were inoculated s.c. with parental or IRE1α KO CT26 cells and tumor growth was measured over 27 days. **(B)** IB analysis of IRE1α expression and activation.





Figure S4. IRE1α inhibition attenuates CT26 tumor growth. (A, B) Animals were inoculated s.c. with parental or IRE1α KO CT26 cells and tumor growth was measured over 27 days. **(B)** IB analysis of IRE1α expression and activation.





Figure S4. IRE1α inhibition attenuates CT26 tumor growth. (D) Mice were inoculated s.c. with CT26 cells, grouped out 7 days afterwards and treated with vehicle or G9668 (250 mg/kg, BID). IB analysis of total tumor lysates is depicted.





Figure S4. IRE1α inhibition attenuates CT26 tumor growth. (D) Mice were inoculated s.c. with CT26 cells, grouped out 7 days afterwards and treated with vehicle or G9668 (250 mg/kg, BID). IB analysis of total tumor lysates is depicted.